These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

261 related items for PubMed ID: 26472021

  • 1. NTRK1 rearrangement in colorectal cancer patients: evidence for actionable target using patient-derived tumor cell line.
    Lee SJ, Li GG, Kim ST, Hong ME, Jang J, Yoon N, Ahn SM, Murphy D, Christiansen J, Wei G, Hornby Z, Lee DW, Park JO, Park YS, Lim HY, Hong SN, Kim SH, Kang WK, Park K, Park WY, Kim KM, Lee J.
    Oncotarget; 2015 Nov 17; 6(36):39028-35. PubMed ID: 26472021
    [Abstract] [Full Text] [Related]

  • 2. Detection of NTRK1/3 Rearrangements in Papillary Thyroid Carcinoma Using Immunohistochemistry, Fluorescent In Situ Hybridization, and Next-Generation Sequencing.
    Lee YC, Chen JY, Huang CJ, Chen HS, Yang AH, Hang JF.
    Endocr Pathol; 2020 Dec 17; 31(4):348-358. PubMed ID: 32880785
    [Abstract] [Full Text] [Related]

  • 3. Sensitivity to Entrectinib Associated With a Novel LMNA-NTRK1 Gene Fusion in Metastatic Colorectal Cancer.
    Sartore-Bianchi A, Ardini E, Bosotti R, Amatu A, Valtorta E, Somaschini A, Raddrizzani L, Palmeri L, Banfi P, Bonazzina E, Misale S, Marrapese G, Leone A, Alzani R, Luo D, Hornby Z, Lim J, Veronese S, Vanzulli A, Bardelli A, Martignoni M, Davite C, Galvani A, Isacchi A, Siena S.
    J Natl Cancer Inst; 2016 Jan 17; 108(1):. PubMed ID: 26563355
    [Abstract] [Full Text] [Related]

  • 4. Detection of novel and potentially actionable anaplastic lymphoma kinase (ALK) rearrangement in colorectal adenocarcinoma by immunohistochemistry screening.
    Lee J, Kim HC, Hong JY, Wang K, Kim SY, Jang J, Kim ST, Park JO, Lim HY, Kang WK, Park YS, Lee J, Lee WY, Park YA, Huh JW, Yun SH, Do IG, Kim SH, Balasubramanian S, Stephens PJ, Ross JS, Li GG, Hornby Z, Ali SM, Miller VA, Kim KM, Ou SH.
    Oncotarget; 2015 Sep 15; 6(27):24320-32. PubMed ID: 26172300
    [Abstract] [Full Text] [Related]

  • 5. The TPM3-NTRK1 rearrangement is a recurring event in colorectal carcinoma and is associated with tumor sensitivity to TRKA kinase inhibition.
    Ardini E, Bosotti R, Borgia AL, De Ponti C, Somaschini A, Cammarota R, Amboldi N, Raddrizzani L, Milani A, Magnaghi P, Ballinari D, Casero D, Gasparri F, Banfi P, Avanzi N, Saccardo MB, Alzani R, Bandiera T, Felder E, Donati D, Pesenti E, Sartore-Bianchi A, Gambacorta M, Pierotti MA, Siena S, Veronese S, Galvani A, Isacchi A.
    Mol Oncol; 2014 Dec 15; 8(8):1495-507. PubMed ID: 24962792
    [Abstract] [Full Text] [Related]

  • 6. Acquired Resistance to the TRK Inhibitor Entrectinib in Colorectal Cancer.
    Russo M, Misale S, Wei G, Siravegna G, Crisafulli G, Lazzari L, Corti G, Rospo G, Novara L, Mussolin B, Bartolini A, Cam N, Patel R, Yan S, Shoemaker R, Wild R, Di Nicolantonio F, Bianchi AS, Li G, Siena S, Bardelli A.
    Cancer Discov; 2016 Jan 15; 6(1):36-44. PubMed ID: 26546295
    [Abstract] [Full Text] [Related]

  • 7. Foretinib Overcomes Entrectinib Resistance Associated with the NTRK1 G667C Mutation in NTRK1 Fusion-Positive Tumor Cells in a Brain Metastasis Model.
    Nishiyama A, Yamada T, Kita K, Wang R, Arai S, Fukuda K, Tanimoto A, Takeuchi S, Tange S, Tajima A, Furuya N, Kinoshita T, Yano S.
    Clin Cancer Res; 2018 May 15; 24(10):2357-2369. PubMed ID: 29463555
    [Abstract] [Full Text] [Related]

  • 8. Elaboration of NTRK-rearranged colorectal cancer: Integration of immunoreactivity pattern, cytogenetic identity, and rearrangement variant.
    Wu S, Liu Y, Shi X, Zhou W, Zeng X.
    Dig Liver Dis; 2023 Dec 15; 55(12):1757-1764. PubMed ID: 37142453
    [Abstract] [Full Text] [Related]

  • 9. Gene fusions and oncogenic mutations in MLH1 deficient and BRAFV600E wild-type colorectal cancers.
    Ukkola I, Nummela P, Kero M, Tammio H, Tuominen J, Kairisto V, Kallajoki M, Haglund C, Peltomäki P, Kytölä S, Ristimäki A.
    Virchows Arch; 2022 Apr 15; 480(4):807-817. PubMed ID: 35237889
    [Abstract] [Full Text] [Related]

  • 10. Chromosomal rearrangements involving the NTRK1 gene in colorectal carcinoma.
    Créancier L, Vandenberghe I, Gomes B, Dejean C, Blanchet JC, Meilleroux J, Guimbaud R, Selves J, Kruczynski A.
    Cancer Lett; 2015 Aug 28; 365(1):107-11. PubMed ID: 26001971
    [Abstract] [Full Text] [Related]

  • 11. Detection of NTRK fusions in glioblastoma: fluorescent in situ hybridisation is more useful than pan-TRK immunohistochemistry as a screening tool prior to RNA sequencing.
    Bourhis A, Caumont C, Quintin-Roué I, Magro E, Dissaux G, Remoué A, Le Noac'h P, Douet-Guilbert N, Seizeur R, Tyulyandina A, Schick U, Merlio JP, Marcorelles P, Cappellen D, Uguen A.
    Pathology; 2022 Feb 28; 54(1):55-62. PubMed ID: 34518039
    [Abstract] [Full Text] [Related]

  • 12. NTRK gene rearrangements are highly enriched in MLH1/PMS2 deficient, BRAF wild-type colorectal carcinomas-a study of 4569 cases.
    Chou A, Fraser T, Ahadi M, Fuchs T, Sioson L, Clarkson A, Sheen A, Singh N, Corless CL, Gill AJ.
    Mod Pathol; 2020 May 28; 33(5):924-932. PubMed ID: 31792356
    [Abstract] [Full Text] [Related]

  • 13. NTRK oncogenic fusions are exclusively associated with the serrated neoplasia pathway in the colorectum and begin to occur in sessile serrated lesions.
    Kim JH, Hong JH, Choi YL, Lee JA, Seo MK, Lee MS, An SB, Sung MJ, Cho NY, Kim SS, Shin YK, Kim S, Kang GH.
    J Pathol; 2021 Dec 28; 255(4):399-411. PubMed ID: 34402529
    [Abstract] [Full Text] [Related]

  • 14. Clinicopathological features and immunohistochemical utility of NTRK-, ALK-, and ROS1-rearranged papillary thyroid carcinomas and anaplastic thyroid carcinomas.
    Nozaki Y, Yamamoto H, Iwasaki T, Sato M, Jiromaru R, Hongo T, Yasumatsu R, Oda Y.
    Hum Pathol; 2020 Dec 28; 106():82-92. PubMed ID: 32980422
    [Abstract] [Full Text] [Related]

  • 15. Durable Clinical Response to Entrectinib in NTRK1-Rearranged Non-Small Cell Lung Cancer.
    Farago AF, Le LP, Zheng Z, Muzikansky A, Drilon A, Patel M, Bauer TM, Liu SV, Ou SH, Jackman D, Costa DB, Multani PS, Li GG, Hornby Z, Chow-Maneval E, Luo D, Lim JE, Iafrate AJ, Shaw AT.
    J Thorac Oncol; 2015 Dec 28; 10(12):1670-4. PubMed ID: 26565381
    [Abstract] [Full Text] [Related]

  • 16. Identification of NTRK gene fusions in lung adenocarcinomas in the Chinese population.
    Zhao R, Yao F, Xiang C, Zhao J, Shang Z, Guo L, Ding W, Ma S, Yu A, Shao J, Zhu L, Han Y.
    J Pathol Clin Res; 2021 Jul 28; 7(4):375-384. PubMed ID: 33768710
    [Abstract] [Full Text] [Related]

  • 17. Prevalence and detection methodology for preliminary exploration of NTRK fusion in gastric cancer from a single-center retrospective cohort.
    Dong K, Yin L, Wang Y, Jia L, Diao X, Huang X, Zhou L, Lin D, Sun Y.
    Hum Pathol; 2024 Jun 28; 148():87-92. PubMed ID: 38653403
    [Abstract] [Full Text] [Related]

  • 18. TRKA expression and NTRK1 gene copy number across solid tumours.
    Mauri G, Valtorta E, Cerea G, Amatu A, Schirru M, Marrapese G, Fiorillo V, Recchimuzzo P, Cavenago IS, Bonazzina EF, Motta V, Lauricella C, Veronese S, Tosi F, Maiolani M, Rospo G, Truini M, Bonoldi E, Christiansen J, Potts SJ, Siena S, Sartore-Bianchi A.
    J Clin Pathol; 2018 Oct 28; 71(10):926-931. PubMed ID: 29802225
    [Abstract] [Full Text] [Related]

  • 19. Mechanisms of Resistance to NTRK Inhibitors and Therapeutic Strategies in NTRK1-Rearranged Cancers.
    Fuse MJ, Okada K, Oh-Hara T, Ogura H, Fujita N, Katayama R.
    Mol Cancer Ther; 2017 Oct 28; 16(10):2130-2143. PubMed ID: 28751539
    [Abstract] [Full Text] [Related]

  • 20. Pan-Trk Immunohistochemistry Is an Efficient and Reliable Screen for the Detection of NTRK Fusions.
    Hechtman JF, Benayed R, Hyman DM, Drilon A, Zehir A, Frosina D, Arcila ME, Dogan S, Klimstra DS, Ladanyi M, Jungbluth AA.
    Am J Surg Pathol; 2017 Nov 28; 41(11):1547-1551. PubMed ID: 28719467
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.